Author Affiliation: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
In a recent issue of JAMA Dermatology, Wells et al1 compare the recommendations of the MelaFind device (Mela Sciences Inc) with those of 39 dermatologists who did not use MelaFind for sensitivity and specificity of melanoma diagnosis. The specificity of the device was so low that I find the conclusions of the authors that it is a useful and “very sensitive tool to guide dermatologists”1(p1084) not supported by their data. The authors report that on a test set of 47 lesions, MelaFind recommended biopsy in 44 lesions and no biopsy in 3. Of the 3 nonbiopsy lesions, 1 was melanoma.
Cukras AR. On the Comparison of Diagnosis and Management of Melanoma Between Dermatologists and MelaFind. JAMA Dermatol. 2013;149(5):622-623. doi:10.1001/jamadermatol.2013.3405